A Phase 3 interventional study of Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one has the largest enrollment, is one of 5 that started in 2024, is one of 11 in phase 3, and was the 50th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 5 started in 2024.
This study's enrollment of 1,126 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 7 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications.
The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's enrollment of 1,126 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria for Participants with nAMD:
History of choroidal neovascularization (CNV) lesions secondary to nAMD in the eye study, requiring continued anti-VEGF treatment, as determined by the investigator.
Key Inclusion Criteria for Participants with DME:
History of DME with central involvement (in the central subfield on Spectral domain optical coherence tomography [SD-OCT]) in the study eye, requiring continued anti-VEGF treatment, as determined by the investigator
Key Inclusion for All Participants:
Key Exclusion Criteria for Participants with nAMD:
Evidence of CNV due to any cause other than nAMD in either eye
Key Exclusion Criteria for Participants with DME:
NOTE: Other protocol defined inclusion / exclusion criteria apply.
Participants previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications
Drug: Aflibercept 8 mg
Administered by intravitreal (IVT) injection
Also known as: EYLEA®HD, BAY86-5321
Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Time frame: Through week 24
Participants With at Least One Serious TEAE
Time frame: Through week 24
1376 participants screened. 1126 participants enrolled. 1110 participants treated.
| Milestone | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema |
|---|---|---|
| Started | 625 | 501 |
| Enrolled and treated | 622 | 488 |
| Completed | 595 | 471 |
| Not completed | 30 | 30 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 20 | 10 |
| Withdrew: Non-compliance | 3 | 13 |
| percentage | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema |
|---|---|---|
| Ocular Treatment-Emergent Adverse Events - Study Eye | 17.0 | 22.3 |
| Ocular Treatment-Emergent Adverse Events - Fellow Eye | 13.0 | 16.4 |
| Non-ocular Treatment-Emergent Adverse Events | 36.8 | 39.3 |
| percentage | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema |
|---|---|---|
| Ocular Treatment-Emergent Serious Adverse Events - Study Eye | 0.2 | 0.8 |
| Ocular Treatment-Emergent Serious Adverse Events - Fellow Eye | 0.3 | 0.2 |
| Non-ocular Treatment-Emergent Serious Adverse Events | 5.0 | 7.2 |
Collected over From the date of informed consent (ICF) signature through Week 24.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neovascular Age-related Macular Degeneration | 2/625 (0.3%) | 34/625 (5.4%) | 0/625 (0%) |
| Diabetic Macular Edema | 4/501 (0.8%) | 40/501 (8%) | 0/501 (0%) |
| Event | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 1/625 | 3/501 |
| AnaemiaBlood and lymphatic system disorders | 0/625 | 3/501 |
| Endophthalmitis Study EyeInfections and infestations | 0/625 | 3/501 |
| SyncopeNervous system disorders | 0/625 | 2/501 |
| Transient ischaemic attackNervous system disorders | 0/625 | 2/501 |
| Acute kidney injuryRenal and urinary disorders | 1/625 | 2/501 |
| Acute myocardial infarctionCardiac disorders | 1/625 | 2/501 |
| Myocardial infarctionCardiac disorders | 2/625 | 2/501 |
| DeathGeneral disorders | 0/625 | 2/501 |
| Mental status changesPsychiatric disorders | 0/625 | 2/501 |
All enrolled participants who received at least 1 injection of aflibercept during the study were included. Due to non-compliance issues, 16 participants were not included in the baseline characteristics and outcome measure analyses. Only 1 eye per participant was enrolled as the "study eye." The non-study eye is then considered as the "fellow eye."
| Age, Continuous(years) | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema | Total |
|---|---|---|---|
| Mean | 77.1 ± 8.5 | 62.8 ± 9.8 | 70.8 ± 11.5 |
| Sex: Female, Male(Participants) | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema | Total |
|---|---|---|---|
| Female | 360 | 203 | 563 |
| Male | 262 | 285 | 547 |
| Ethnicity (NIH/OMB)(Participants) | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema | Total |
|---|---|---|---|
| Hispanic or Latino | 43 | 114 | 157 |
| Not Hispanic or Latino | 566 | 371 | 937 |
| Unknown or Not Reported | 13 | 3 | 16 |
| Race (NIH/OMB)(Participants) | Neovascular Age-related Macular Degeneration | Diabetic Macular Edema | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 21 | 38 | 59 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 8 | 51 | 59 |
| White | 589 | 387 | 976 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 2 | 9 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued developed of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Jul 2024 to primary completion in Aug 2025, 13 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 13 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept